Fundz

Ractigen Therapeutics raises over $31M in a funding round led by Guozhong Capital to accelerate clinical development of saRNA therapeutics.

PRIVATEJul 30, 2026

Amount Raised

$31 Million

Round Type

Venture

NantongHealth CareScience And Engineering

Investors

Snd Financial HoldingsLongmen CapitalIDG CapitalChina Everbright LimitedJolmo CapitalWin Win CapitalGuozhong Capital

Description

Ractigen Therapeutics, a Shanghai-based biotechnology company, raised over $31M in funding. This round was led by Guozhong Capital and included various other investors. The funds will be used to advance clinical trials for their saRNA assets. The company has three differentiated assets in clinical-stage development.

Quick answer

Ractigen Therapeutics raised $31 Million in a funding round, dated July 30, 2026. Investors: Snd Financial Holdings, Longmen Capital, IDG Capital, China Everbright Limited, Jolmo Capital, Win Win Capital and Guozhong Capital. Ractigen Therapeutics is based in Nantong, Jiangsu, China.

How much did Ractigen Therapeutics raise?
Ractigen Therapeutics raised $31 Million in a funding round on July 30, 2026.
Who invested in Ractigen Therapeutics?
Snd Financial Holdings, Longmen Capital, IDG Capital, China Everbright Limited, Jolmo Capital, Win Win Capital and Guozhong Capital are named as investors in this round.
What does Ractigen Therapeutics do?
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang.
Where is Ractigen Therapeutics based and how big is it?
Ractigen Therapeutics is based in Nantong, Jiangsu, China. Fundz records about 18 employees.
Who are the decision-makers at Ractigen Therapeutics?
Fundz holds 1 contact at Ractigen Therapeutics, including the Co-founder, President & CEO. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Health Care around the same time

Companies in the same sectors as Ractigen Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • IMPLICITY raised $41M on September 9, 2026.
  • HealthSnap raised $25M (Debt Financing) on August 6, 2026.
  • Alzamend Neuro raised $7.5M (Series D) on August 4, 2026.
  • RedHill Biopharma Ltd raised $6M (Post-IPO Equity) on June 18, 2026.
  • Tandem Health raised $100M (Series B) on September 13, 2026.
  • David Protein raised $250M (Series B) on September 13, 2026.

Who to call at Ractigen Therapeutics, and when

A new round usually means Ractigen Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ractigen Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ractigen Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ractigen Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ractigen Therapeutics

Location

Nantong, Jiangsu, China

About

Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, Ractigen Therapeutics has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders. Ractigen Therapeuticswww.ractigen.com SOURCE Ractigen Therapeutics

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ractigen Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsLong-Cheng, Co-founder, President & CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Ractigen Therapeutics's next move

See what Strategic adds

Ractigen Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.